In silico target fishing: Predicting biological targets from chemical structure

[1]  Vladimir Poroikov,et al.  How to acquire new biological activities in old compounds by computer prediction , 2002, J. Comput. Aided Mol. Des..

[2]  Y.Z. Chen,et al.  Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.

[3]  C. Hart,et al.  Finding the target after screening the phenotype. , 2005, Drug discovery today.

[4]  Meir Glick,et al.  Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..

[5]  Ajay N. Jain,et al.  Robust ligand-based modeling of the biological targets of known drugs. , 2006, Journal of medicinal chemistry.

[6]  Robert P. Sheridan,et al.  Calculating Similarities between Biological Activities in the MDL Drug Data Report Database , 2004, J. Chem. Inf. Model..

[7]  Ruili Huang,et al.  Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action. , 2006, Journal of medicinal chemistry.

[8]  Z. Deng,et al.  Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. , 2004, Journal of medicinal chemistry.

[9]  Andrea Zaliani,et al.  A Knowledge-Based Weighting Approach to Ligand-Based Virtual Screening , 2006, J. Chem. Inf. Model..

[10]  Ruili Huang,et al.  Linking tumor cell cytotoxicity to mechanism of drug action: An integrated analysis of gene expression, small‐molecule screening and structural databases , 2005, Proteins.

[11]  Peripheral benzodiazepine ligands inhibit aggregation and thromboxane synthesis induced by arachidonic acid in rabbit platelets in vitro. , 1995, Thrombosis research.

[12]  Stephan Heyse,et al.  From targets to leads: the importance of advanced data analysis for decision support in drug discovery. , 2005, Current opinion in drug discovery & development.

[13]  Tudor I. Oprea,et al.  Post-High-Throughput Screening Analysis: An Empirical Compound Prioritization Scheme , 2005, Journal of biomolecular screening.

[14]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[15]  F. Sheinerman,et al.  High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding. , 2005, Journal of molecular biology.

[16]  A. Fliri,et al.  Biospectra analysis: model proteome characterizations for linking molecular structure and biological response. , 2005, Journal of medicinal chemistry.

[17]  Ajay N. Jain.  Morphological similarity: A 3D molecular similarity method correlated with protein-ligand recognition , 2000, J. Comput. Aided Mol. Des..

[18]  P. Beroza,et al.  Chemoproteomics as a basis for post-genomic drug discovery. , 2002, Drug discovery today.

[19]  E. Sausville,et al.  Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. , 2002, Journal of medicinal chemistry.

[20]  Dragos Horvath,et al.  Predicting ADME properties and side effects: the BioPrint approach. , 2003, Current opinion in drug discovery & development.

[21]  David M. Rocke,et al.  Predicting ligand binding to proteins by affinity fingerprinting. , 1995, Chemistry & biology.

[22]  N. Paul,et al.  Recovering the true targets of specific ligands by virtual screening of the protein data bank , 2004, Proteins.

[23]  E. Jacoby,et al.  Chemogenomics: an emerging strategy for rapid target and drug discovery , 2004, Nature Reviews Genetics.

[24]  Pierre Acklin,et al.  Similarity Metrics for Ligands Reflecting the Similarity of the Target Proteins , 2003, J. Chem. Inf. Comput. Sci..

[25]  Robert C. Glen,et al.  Chapter 9 Molecular Similarity: Advances in Methods, Applications and Validations in Virtual Screening and QSAR , 2006, Annual Reports in Computational Chemistry.

[26]  Z. Deng,et al.  Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. , 2006, Journal of medicinal chemistry.

[27]  C. E. Peishoff,et al.  A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.

[28]  Vladimir Poroikov,et al.  PASS: prediction of activity spectra for biologically active substances , 2000, Bioinform..

[29]  Ruili Huang,et al.  Evaluating Chemical Structure Similarity as an Indicator of Cellular Growth Inhibition , 2006, J. Chem. Inf. Model..

[30]  Gavin Harper,et al.  Training Similarity Measures for Specific Activities: Application to Reduced Graphs , 2006, J. Chem. Inf. Model..

[31]  G. Rosania,et al.  Supertargeted chemistry: identifying relationships between molecular structures and their sub-cellular distribution. , 2003, Current topics in medicinal chemistry.

[32]  Tudor I. Oprea,et al.  WOMBAT: World of Molecular Bioactivity , 2005 .

[33]  A. Fliri,et al.  Biological spectra analysis: Linking biological activity profiles to molecular structure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Niwa.  Prediction of biological targets using probabilistic neural networks and atom-type descriptors. , 2004, Journal of medicinal chemistry.

[35]  R. Glen,et al.  Ligand-protein docking: cancer research at the interface between biology and chemistry. , 2003, Current medicinal chemistry.

[36]  Stuart L. Schreiber,et al.  Using High-Throughput Screening Data To Discriminate Compounds with Single-Target Effects from Those with Side Effects , 2006, J. Chem. Inf. Model..

[37]  Andreas Bender,et al.  "Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept? , 2006, J. Chem. Inf. Model..

[38]  Jürgen Bajorath,et al.  Mapping Algorithms for Molecular Similarity Analysis and Ligand-Based Virtual Screening: Design of DynaMAD and Comparison with MAD and DMC , 2006, J. Chem. Inf. Model..

[39]  Rapid computational identification of the targets of protein kinase inhibitors. , 2006, Current opinion in drug discovery & development.

[40]  J. Dearden,et al.  Design of new cognition enhancers: from computer prediction to synthesis and biological evaluation. , 2004, Journal of medicinal chemistry.